Drug repositioning is a successful approach in medicinal research. It significantly simplifies the long-term process of clinical drug evaluation, since the drug being tested has already been approved for another condition. One example of drug repositioning involves cardiac glycosides (CGs), which have, for a long time, been used in heart medicine. Moreover, it has been known for decades that CGs also have great potential in cancer treatment and, thus, many clinical trials now evaluate their anticancer potential. Interestingly, heart failure and cancer are not the only conditions for which CGs could be effectively used. In recent years, the antiviral potential of CGs has been extensively studied, and with the ongoing SARS-CoV-2 pandemic, this interest in CGs has increased even more. Therefore, here, we present CGs as potent and promising antiviral compounds, which can interfere with almost any steps of the viral life cycle, except for the viral attachment to a host cell. In this review article, we summarize the reported data on this hot topic and discuss the mechanisms of antiviral action of CGs, with reference to the particular viral life cycle phase they interfere with.
- Klíčová slova
- COVID-19, Na+/K+-ATPase, cardiac steroids, coronavirus, digitoxin, digoxin, drug repurposing, lanatoside C, ouabain, virus entry,
- MeSH
- antivirové látky farmakologie terapeutické užití MeSH
- COVID-19 MeSH
- digitoxin MeSH
- digoxin MeSH
- internalizace viru účinky léků MeSH
- lidé MeSH
- nádory farmakoterapie MeSH
- ouabain MeSH
- pandemie MeSH
- přehodnocení terapeutických indikací léčivého přípravku metody MeSH
- replikace viru účinky léků MeSH
- SARS-CoV-2 MeSH
- sodíko-draslíková ATPasa MeSH
- srdeční glykosidy metabolismus terapeutické užití MeSH
- srdeční selhání farmakoterapie virologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antivirové látky MeSH
- digitoxin MeSH
- digoxin MeSH
- ouabain MeSH
- sodíko-draslíková ATPasa MeSH
- srdeční glykosidy MeSH
